The DOI matches its Crossref record.
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody
Open accessAbstract
The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein, with an extracellular ligand-binding domain and intracellular tyrosine kinase domain. Ligand binding induces EGFR dimerization and autophosphorylation on several tyrosine residues in the intracellular domain, leading to mitogenic signal transduction. EGFR overexpression correlates with a poor prognosis and is often associated with malignant transformation in a variety of epithelial cancers. ABX-EGF is a high-affinity (dissociation constant K(D) = 5 x 10(-11) M) fully human IgG2 monoclonal antibody against human EGFR. ABX-EGF binds EGFR and blocks receptor binding of EGF and transforming growth factor-alpha, inhibiting EGFR tyrosine phosphorylation and tumor cell activation. ABX-EGF prevents tumor formation and eradicates large, established A431 tumors in xenograft models. Tumor growth inhibition occurs at relatively low doses, without concomitant chemotherapy or radiotherapy. When combined with chemotherapeutic agents, ABX-EGF has resulted in additive antitumor activity. A Phase I clinical trial has demonstrated activity in several tumor types, and the results from a Phase II trial for renal cell cancer also showed modest activity. Therapy was generally well tolerated without statistically significant adverse events. Monoclonal antibody blockade of EGFR represents a new and exciting direction in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Self-citationSegaert, S., & Van Cutsem, E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi279 · Cited by 571
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies
Yewale, C., Baradia, D., Vhora, I., Patil, S., & Misra, A. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.100 · Cited by 533
EGFR Signaling and Drug Discovery
Lurje, G., & Lenz, H.-J. (2009) · Oncology · doi:10.1159/000279388 · Cited by 442
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents
Tabernero, J. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0404 · Cited by 437
Human antibodies from transgenic animals.
Lonberg, N. (2005) · Nature Biotechnology · doi:10.1038/nbt1135 · Cited by 434
RENAL CELL CARCINOMA 2005: NEW FRONTIERS IN STAGING, PROGNOSTICATION AND TARGETED MOLECULAR THERAPY
LAM, J. S., SHVARTS, O., LEPPERT, J. T., FIGLIN, R. A., & BELLDEGRUN, A. S. (2005) · Journal of Urology · doi:10.1097/01.ju.0000165693.68449.c3 · Cited by 372
Self-citationEfficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies
Roovers, R. C., Laeremans, T., Huang, L., De Taeye, S., Verkleij, A. J., Revets, H., de Haard, H. J., & van Bergen en Henegouwen, P. M. P. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0180-4 · Cited by 346
Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers
Widakowich, C., de Castro, G., de Azambuja, E., Dinh, P., & Awada, A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1443 · Cited by 324
Stabile, L. P., Lyker, J. S., Gubish, C. T., Zhang, W., Grandis, J. R., & Siegfried, J. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1872 · Cited by 309
Scope, A., Agero, A. L. C., Dusza, S. W., Myskowski, P. L., Lieb, J. A., Saltz, L., Kemeny, N. E., & Halpern, A. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6987 · Cited by 278
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
Troiani, T., Napolitano, S., Della Corte, C. M., Martini, G., Martinelli, E., Morgillo, F., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000088 · Cited by 104
Cohen, M. S., Al-kasspooles, M. F., Williamson, S. K., Henry, D., Broward, M., & Roby, K. F. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0669-0 · Cited by 17
Metadata
- Authors
- Foon, K. A., Yang, X.-D., Weiner, L. M., Belldegrun, A. S., Figlin, R. A., Crawford, J., Rowinsky, E. K., Dutcher, J. P., Vogelzang, N. J., Gollub, J., Thompson, J. A., Schwartz, G., Bukowski, R. M., Roskos, L. K., & Schwab, G. M.
- Venue
- International Journal of Radiation Oncology*Biology*Physics
- Publisher
- Elsevier BV
- Published
- 2004-03
- Volume
- 58
- Issue
- 3
- Pages
- 984-990
- ISSN
- 0360-3016 (ISSN-L)
- OpenAlex
- W2019195072
- Cited by
- 218
- References
- 0
- FWCI
- 11.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.